Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
239 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Nephropathy - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Diabetic Nephropathy - Pipeline Review, H1 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Diabetic Nephropathy Overview 10 Therapeutics Development 11 Pipeline Products for Diabetic Nephropathy - Overview 11 Pipeline Products for Diabetic Nephropathy - Comparative Analysis 12 Diabetic Nephropathy - Therapeutics under Development by Companies 13 Diabetic Nephropathy - Therapeutics under Investigation by Universities/Institutes 18 Diabetic Nephropathy - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Diabetic Nephropathy - Products under Development by Companies 23 Diabetic Nephropathy - Products under Investigation by Universities/Institutes 27 Diabetic Nephropathy - Companies Involved in Therapeutics Development 28 AbbVie Inc. 28 Aerpio Therapeutics, Inc. 29 Antisense Therapeutics Limited 30 Astellas Pharma Inc. 31 AstraZeneca PLC 32 Bayer AG 33 Bristol-Myers Squibb Company 34 Cellmid Limited 35 ChemoCentryx, Inc. 36 Concert Pharmaceuticals, Inc. 37 CTI BioPharma Corp. 38 Daiichi Sankyo Company, Limited 39 DiaMedica Inc. 40 Dimerix Bioscience Pty Ltd 41 Dong Wha Pharma Co., Ltd. 42 Eli Lilly and Company 43 Galectin Therapeutics, Inc. 44 GenKyoTex S.A. 45 Gentium S.p.A. 46 Gilead Sciences, Inc. 47 GlaxoSmithKline plc 48 Glucox Biotech AB 49 GNI Group Ltd. 50 IMMD Inc. 51 Intercept Pharmaceuticals, Inc. 52 InterMune, Inc. 53 Inventiva SAS 54 Islet Sciences, Inc. 55 Jenrin Discovery, Inc. 56 Johnson & Johnson 57 Mallinckrodt plc 58 Mesoblast Limited 59 Mitsubishi Tanabe Pharma Corporation 60 NephroGenex, Inc. 61 Noxxon Pharma AG 62 Omeros Corporation 63 OncoImmune, Inc. 64 Otsuka Holdings Co., Ltd. 65 Pfizer Inc. 66 PhytoHealth Corporation 67 ProMetic Life Sciences Inc. 68 Serodus ASA 69 Shire Plc 70 Thrasos, Inc. 71 Torrent Pharmaceuticals Limited 72 Vascular Pharmaceuticals, Inc. 73 Diabetic Nephropathy - Therapeutics Assessment 74 Assessment by Monotherapy Products 74 Assessment by Target 75 Assessment by Mechanism of Action 78 Assessment by Route of Administration 81 Assessment by Molecule Type 83 Drug Profiles 85 11-RVIVIT - Drug Profile 85 A-717 - Drug Profile 86 APX-115 - Drug Profile 87 ASP-7657 - Drug Profile 88 ASP-8232 - Drug Profile 89 ATL-1103 - Drug Profile 90 atrasentan hydrochloride - Drug Profile 92 baricitinib - Drug Profile 94 BMS-813160 - Drug Profile 97 canagliflozin - Drug Profile 98 CCX-140 - Drug Profile 100 corticotropin - Drug Profile 102 CS-3150 - Drug Profile 104 CTP-499 - Drug Profile 106 Cyndacel-M - Drug Profile 108 DCB-DN1 - Drug Profile 109 DM-199 - Drug Profile 110 DMX-250 - Drug Profile 112 Drug for Diabetic Nephropathy - Drug Profile 113 Drugs to Activate Nrf2 for Diabetic Cardiomyopathy - Drug Profile 114 DT-23552 - Drug Profile 115 DW-1029M - Drug Profile 116 emapticap pegol - Drug Profile 117 finerenone - Drug Profile 119 GKT-136901 - Drug Profile 120 GKT-137831 - Drug Profile 122 GKT-901 - Drug Profile 123 GR-MD-02 - Drug Profile 124 GS-4997 - Drug Profile 126 GW-610742 - Drug Profile 127 hu-91 - Drug Profile 129 IMD-1041 - Drug Profile 131 INT-767 - Drug Profile 132 JD-5037 - Drug Profile 134 JNJ-39933673 - Drug Profile 135 KBP-5074 - Drug Profile 136 lisofylline - Drug Profile 137 Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 139 Monoclonal Antibody to Inhibit HPTPbeta for Diabetic Nephropathy - Drug Profile 141 Monoclonal Antibody to Inhibit Midkine for Cancer and Inflammatory Disorders - Drug Profile 142 MSC300-IV - Drug Profile 143 MT-3995 - Drug Profile 145 Nephrilin - Drug Profile 146 Oligotide - Drug Profile 147 OX-029 - Drug Profile 149 PBI-4050 - Drug Profile 150 PF-00489791 - Drug Profile 151 PF-04634817 - Drug Profile 152 PF-06409577 - Drug Profile 153 PHN-033 - Drug Profile 154 pirfenidone - Drug Profile 155 pirfenidone - Drug Profile 158 probucol - Drug Profile 160 Pyridoxamine Dihydrochloride - Drug Profile 161 Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 163 SER-150 - Drug Profile 164 SHP-627 - Drug Profile 166 Small Molecule for Diabetic Nephropathy - Drug Profile 167 Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy - Drug Profile 168 Small Molecules for Diabetic Nephropathy - Drug Profile 169 Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 170 SP-20202 - Drug Profile 172 THRV-123 - Drug Profile 173 TRC-120038 - Drug Profile 174 VPI-2690-B - Drug Profile 175 Diabetic Nephropathy - Recent Pipeline Updates 177 Diabetic Nephropathy - Dormant Projects 224 Diabetic Nephropathy - Discontinued Products 226 Diabetic Nephropathy - Product Development Milestones 227 Featured News & Press Releases 227 Appendix 234 Methodology 234 Coverage 234 Secondary Research 234 Primary Research 234 Expert Panel Validation 234 Contact Us 234 Disclaimer 235
List of Tables Number of Products under Development for Diabetic Nephropathy, H1 2015 15 Number of Products under Development for Diabetic Nephropathy - Comparative Analysis, H1 2015 16 Number of Products under Development by Companies, H1 2015 18 Number of Products under Development by Companies, H1 2015 (Contd..1) 19 Number of Products under Development by Companies, H1 2015 (Contd..2) 20 Number of Products under Development by Companies, H1 2015 (Contd..3) 21 Number of Products under Investigation by Universities/Institutes, H1 2015 22 Comparative Analysis by Late Stage Development, H1 2015 23 Comparative Analysis by Clinical Stage Development, H1 2015 24 Comparative Analysis by Early Stage Development, H1 2015 25 Comparative Analysis by Unknown Stage Development, H1 2015 26 Products under Development by Companies, H1 2015 27 Products under Development by Companies, H1 2015 (Contd..1) 28 Products under Development by Companies, H1 2015 (Contd..2) 29 Products under Development by Companies, H1 2015 (Contd..3) 30 Products under Investigation by Universities/Institutes, H1 2015 31 Diabetic Nephropathy - Pipeline by AbbVie Inc., H1 2015 32 Diabetic Nephropathy - Pipeline by Aerpio Therapeutics, Inc., H1 2015 33 Diabetic Nephropathy - Pipeline by Antisense Therapeutics Limited, H1 2015 34 Diabetic Nephropathy - Pipeline by Astellas Pharma Inc., H1 2015 35 Diabetic Nephropathy - Pipeline by AstraZeneca PLC, H1 2015 36 Diabetic Nephropathy - Pipeline by Bayer AG, H1 2015 37 Diabetic Nephropathy - Pipeline by Bristol-Myers Squibb Company, H1 2015 38 Diabetic Nephropathy - Pipeline by Cellmid Limited, H1 2015 39 Diabetic Nephropathy - Pipeline by ChemoCentryx, Inc., H1 2015 40 Diabetic Nephropathy - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 41 Diabetic Nephropathy - Pipeline by CTI BioPharma Corp., H1 2015 42 Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 43 Diabetic Nephropathy - Pipeline by DiaMedica Inc., H1 2015 44 Diabetic Nephropathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2015 45 Diabetic Nephropathy - Pipeline by Dong Wha Pharma Co., Ltd., H1 2015 46 Diabetic Nephropathy - Pipeline by Eli Lilly and Company, H1 2015 47 Diabetic Nephropathy - Pipeline by Galectin Therapeutics, Inc., H1 2015 48 Diabetic Nephropathy - Pipeline by GenKyoTex S.A., H1 2015 49 Diabetic Nephropathy - Pipeline by Gentium S.p.A., H1 2015 50 Diabetic Nephropathy - Pipeline by Gilead Sciences, Inc., H1 2015 51 Diabetic Nephropathy - Pipeline by GlaxoSmithKline plc, H1 2015 52 Diabetic Nephropathy - Pipeline by Glucox Biotech AB, H1 2015 53 Diabetic Nephropathy - Pipeline by GNI Group Ltd., H1 2015 54 Diabetic Nephropathy - Pipeline by IMMD Inc., H1 2015 55 Diabetic Nephropathy - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 56 Diabetic Nephropathy - Pipeline by InterMune, Inc., H1 2015 57 Diabetic Nephropathy - Pipeline by Inventiva SAS, H1 2015 58 Diabetic Nephropathy - Pipeline by Islet Sciences, Inc., H1 2015 59 Diabetic Nephropathy - Pipeline by Jenrin Discovery, Inc., H1 2015 60 Diabetic Nephropathy - Pipeline by Johnson & Johnson, H1 2015 61 Diabetic Nephropathy - Pipeline by Mallinckrodt plc, H1 2015 62 Diabetic Nephropathy - Pipeline by Mesoblast Limited, H1 2015 63 Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 64 Diabetic Nephropathy - Pipeline by NephroGenex, Inc., H1 2015 65 Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H1 2015 66 Diabetic Nephropathy - Pipeline by Omeros Corporation, H1 2015 67 Diabetic Nephropathy - Pipeline by OncoImmune, Inc., H1 2015 68 Diabetic Nephropathy - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 69 Diabetic Nephropathy - Pipeline by Pfizer Inc., H1 2015 70 Diabetic Nephropathy - Pipeline by PhytoHealth Corporation, H1 2015 71 Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc., H1 2015 72 Diabetic Nephropathy - Pipeline by Serodus ASA, H1 2015 73 Diabetic Nephropathy - Pipeline by Shire Plc, H1 2015 74 Diabetic Nephropathy - Pipeline by Thrasos, Inc., H1 2015 75 Diabetic Nephropathy - Pipeline by Torrent Pharmaceuticals Limited, H1 2015 76 Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals, Inc., H1 2015 77 Assessment by Monotherapy Products, H1 2015 78 Number of Products by Stage and Target, H1 2015 80 Number of Products by Stage and Mechanism of Action, H1 2015 83 Number of Products by Stage and Route of Administration, H1 2015 86 Number of Products by Stage and Molecule Type, H1 2015 88 Diabetic Nephropathy Therapeutics - Recent Pipeline Updates, H1 2015 181 Diabetic Nephropathy - Dormant Projects, H1 2015 228 Diabetic Nephropathy - Dormant Projects (Contd..1), H1 2015 229 Diabetic Nephropathy - Discontinued Products, H1 2015 230
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
